论文部分内容阅读
柳氮磺胺吡啶(SASP)是治疗轻中度活动性溃疡性结肠炎或维持缓解的有效药物,但因其副作用发生率高达21%以上而限制其应用。5-氨基水杨酸(5-ASA)是该药的活性成分,对局部肠粘膜炎症有治疗作用。本文研究在于确定对 SASP 有副作用的溃疡性结肠炎患者服用5-ASA 的缓解率和副作用发生率,对用5-ASA 有效的患者并进一步评价其在维持缓解方面的作用。方法 85例活动性溃疡性结肠炎,其中51例对小量(2g/d)SASP 有副作用而需停药。本研究分两
Sulfasalazine (SASP) is a potent drug for the treatment of or maintenance of mild to moderate active ulcerative colitis, but its use is limited by the high incidence of side effects of up to 21%. 5-Aminosalicylic acid (5-ASA) is the active ingredient of the drug and has a therapeutic effect on local intestinal mucosal inflammation. The aim of this study was to determine the rates of 5-ASA remission and side effects in patients with ulcerative colitis that have adverse effects on SASP, and to further evaluate the role of 5-ASA in maintaining remission. Methods 85 cases of active ulcerative colitis, of which 51 cases of small doses (2g / d) SASP side effects need to be discontinued. The research is divided into two parts